Jennifer Cotter

Assistant Professor of Clinical Pathology

University of Southern California Norris Comprehensive Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Jennifer Cotter is an Assistant Professor at the University of Southern California Norris Comprehensive Cancer Center in the United States. Her research primarily focuses on pediatric central nervous system tumors, including comparative analyses of glioma and chordoma, as well as innovative diagnostic techniques involving liquid biopsies. Recent publications reflect her expertise in the evaluation and diagnosis of both common and rare pediatric brain tumors.

Articles (20)

Year:

2026

We report a rare case of gestational alloimmune liver disease (GALD) and congenital athymia in a 3-week-old premature male neonate, born via in vitro fertilization (IVF) surrogacy. The neonate initially presented with disseminated intravascular coagulation and septic shock, and subsequently developed liver failure. Despite aggressive treatment, he succumbed. Autopsy confirmed GALD, congenital athymia, splenomegaly, and extensive hemorrhage in the gastrointestinal mucosa and brain. Congenital athymia, characterized by a lack of functional T cells, might impair immune regulation or tolerance mechanisms and reduce the neonate’s capacity to recover from GALD-induced liver injury. The additional context of an IVF surrogate pregnancy further complicates the immunologic landscape. This case highlights the need for further investigation into potential causal or synergistic relationships among these conditions to optimize management strategies for affected neonates.

Year:

2026

Abnormalities of myofiber size are often of diagnostic significance on skeletal muscle biopsies, mainly when myofibers are excessively small. The establishment of standards for myofiber size in children has been hampered until recently by the lack of tools to assess large numbers of fibers across a sizeable number of samples. This study describes the assessment of myofiber size in 349 histologically normal patient biopsy specimens obtained between 4 weeks and 25 years of life and corresponding primarily to locations in the thigh/quadriceps/vastus lateralis region. Biopsy specimens were selected for inclusion based on histologically normal light microscopic findings and minimal technical artifacts. H&E-stained slides were scanned and evaluated for minFeret diameter using a Visiopharm software app (APP #10164). MinFeret diameter fiber size data were then grouped into 18 age cohorts to establish normal ranges for males and females within each age cohort. A pilot study to compare known abnormal cases to these normal ranges was then performed to demonstrate how cases with abnormal fiber size might compare to these standards. This dataset provides a user-friendly and applicable set of standard fiber size ranges to assist in diagnostic and scientific work in children and young adults.

Year:

2025

Osteosarcoma is the most common malignant bone tumor in young patients and remains a significant clinical challenge, particularly at the metastatic stage. Studies detailing the immunosuppressive mechanisms within the metastatic osteosarcoma microenvironment are needed to elucidate the cellular communities in the metastatic microenvironment that support metastatic growth and to identify therapeutic approaches to target the cross-talk between cancer cells and their microenvironment. In this study, we performed spatial transcriptional profiling on a cohort of osteosarcoma pulmonary metastases from pediatric patients. The data revealed a conserved spatial gene expression pattern resembling a foreign body granuloma, characterized by peripheral inflammatory signaling, fibrocollagenous encapsulation, lymphocyte exclusion, and peritumoral macrophage accumulation. The intratumoral microenvironment of these lesions, however, lacked inflammatory signaling. Exploration of spatially distinct drug–gene interactions identified the CXCR4 signaling axis, which displayed spatial heterogeneity and complexity, as a potential therapeutic target that bridges both the intra- and extratumoral microenvironments. Collectively, this study reveals that metastatic osteosarcoma comprises multiple regionally distinct immunosuppressive microenvironments. Significance: Exploration of spatially resolved microenvironments in metastatic osteosarcoma tissues reveals how the tissue architecture promotes immunosuppression and identifies actionable processes to enhance immunotherapy efficacy.

Year:

2025

Distribution and abundance of genes encoding functional and phenotypic macrophage markers. Clustered dot plots illustrating the spatial distribution of gene encoding different functional and phenotypic macrophage markers within each individual metastatic osteosarcoma specimen. The color bar above each dot plot corresponds to the different spatial clusters displayed on the adjoining spatial cluster maps that are shown for reference (above). Separate color palettes denote the independent clustering analysis of each specimen. Spatial clusters were localized to the extratumoral (black) or intratumoral (gray) microenvironments as depicted in the second color bar.

Year:

2025

Differential gene expression of chemokine/cytokines in primary versus metastatic osteosarcoma specimens. Volcano plot of differentially expressed chemokine and cytokine genes in non-metastatic (black dots) and pulmonary metastases (gray dots) from the Sorenson, and colleagues NanoString IO360 gene expression dataset (27). Horizontal red line indicates significance threshold (q = 0.001). Dots with red outline indicates q

Year:

2025

Chemokine/cytokine antibody array profiling in metastatic osteosarcoma patient specimens and patient derived cell lines. Heatmaps showing normalized protein expression of chemokines and cytokines from (A) an independent cohort of 10 frozen metastatic osteosarcoma specimens and (B) conditioned media from five unrelated patient derived cell lines.

Year:

2025

Spatial expression patterns of CSF1R, PTGES2, MARCO, and S100A9. Spatial feature plots showing the regional expression of CSF1R, PTGES2, MARCO, and S100A. The Osteosarcoma Signatures is shown as a reference to identify the intratumoral microenvironment. MARCO expression was either not expressed or below the quality control threshold for specimen OS-9 and thus the feature plot was omitted.

Year:

2025

Little is known about the genomic alterations in chordoma, with the exception of loss of SMARCB1, a core member of the SWI/SNF complex, in poorly differentiated chordomas. A TBXT duplication and rs2305089 polymorphism, located at 6q27, are known genetic susceptibility loci. A comprehensive genomic analysis of the nuclear and mitochondrial genomes in pediatric chordoma has not yet been reported. In this study, we performed WES and mtDNA genome sequencing on 29 chordomas from 23 pediatric patients. Findings were compared with that from whole-genome sequencing datasets of 80 adult patients with skull base chordoma. In the pediatric chordoma cohort, 81% of the somatic mtDNA mutations were observed in NADH complex genes, which is significantly enriched compared with the rest of the mtDNA genes (P = 0.001). In adult chordomas, mtDNA mutations were also enriched in the NADH complex genes (P < 0.0001). Furthermore, a progressive increase in heteroplasmy of nonsynonymous mtDNA mutations was noted in patients with multiple tumors (P = 0.0007). In the nuclear genome, rare likely germline in-frame indels in ARID1B, a member of the SWI/SNF complex located at 6q25.3, were observed in five pediatric patients (22%) and four patients in the adult cohort (5%). The frequency of rare ARID1B indels in the pediatric cohort is significantly higher than that in the adult cohort (P = 0.0236, Fisher’s exact test), but they were both significantly higher than that in the ethnicity-matched populations (P < 5.9e−07 and P < 0.0001174, respectively). Implications: germline ARID1B indels and mtDNA aberrations seem important for chordoma genesis, especially in pediatric chordoma.

Year:

2024

Background The frequency and significance of IDH mutations in glioma across age groups are incompletely understood. We performed a multi-center retrospective age-stratified comparison of patients with IDH-mutant gliomas to identify age-specific differences in clinico-genomic features, treatments, and outcomes. Methods Clinical, histologic, and sequencing data from patients with IDH-mutant, grades 2–4 gliomas, were collected from collaborating institutions between 2013 and 2019. Patients were categorized as pediatric (<19 years), young adult (YA; 19–39 years), or older adult (≥40 years). Clinical presentation, treatment, histologic, and molecular features were compared across age categories using Fisher’s exact test or analysis-of-variance. Cox proportional-hazards regression was used to determine the association of age and other covariates with overall (OS) and progression-free survival (PFS). Results We identified a cohort of 379 patients (204 YA) with IDH-mutant glioma with clinical data. There were 155 (41%) oligodendrogliomas and 224 (59%) astrocytomas. YA showed significantly shorter PFS and shorter median time-to-malignant transformation (MT) compared to pediatric and adult groups, but no significant OS difference. Adjusting for pathology type, extent of resection, and upfront therapy in multivariable analysis, the YA group was independently prognostic of shorter PFS than pediatric and adult groups. Among astrocytomas, CDK4/6 copy number amplifications were associated with both shorter PFS and shorter OS. Among oligodendrogliomas, PIK3CA and CDKN2A/2B alterations were associated with shorter OS. Conclusions IDH-mutant glioma YA patients had significantly shorter PFS and time to MT but did not differ in OS compared to pediatric and adult groups. Treatment approaches varied significantly by patient age and warrant further study as addressable age-associated outcome drivers.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (11)

Benita Tamrazi

University of Southern California

UNITED STATES
View details

Hesamedin Hakimjavadi

Assistant Professor

Medical College of Wisconsin

UNITED STATES
View details

Steven Cen

Associate Professor of Research

University of Southern California

UNITED STATES
View details

Steven Moore

Professor

University of Iowa Healthcare

UNITED STATES
View details

Amy Kathleen LeBlanc

Director and Senior Scientist

National Cancer Institute

UNITED STATES
View details

Xiaowu gai

Professor

Medical College of Wisconsin

UNITED STATES
View details

JAMES CRONK

Assistant Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Nitin Wadhwani

Associate Professor

Ann and Robert H Lurie Children's Hospital of Chicago

UNITED STATES
View details

Jaclyn Biegel

Professor of Clinical Pathology

Children's Hospital of Los Angeles

UNITED STATES
View details

Karra A Jones

Associate Professor

Duke University

UNITED STATES
View details

Rosandra Kaplan

Principal Investigator

National Cancer Institute

UNITED STATES
View details